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A NEW WAY OF MODELING A CLASSIC ORGAN 
 
Michael J Churchill 
 
In this study, we show that removal of a quorum sensing subtype of stromal macrophage 
expands the support capacity of ex vivo bone marrow culture.  Notably, this system maintains much 
of the remaining paracrine signaling of the organ, unlike traditional macrophage ablation or 
cytokine supplemented media and does not place undue stress on the HSPC itself.  Recent studies 
have independently identified alternatively activated macrophages that suppress hematopoiesis in 
in vitro culture.  We have identified for the first time, a small molecule capable of preferentially 
killing those cells, thus providing a method to both culture unaltered HSPC ex vivo for long periods 
of time and significantly expand transient progenitor cells to assist transplantation efficiency.  Our 
culture system in unique in its ability to maintain cultured HSPC in the physiological micro-
environment of the bone marrow 
We found the small molecule “999” capable of expanding hematopoietic capacity of 
stroma culture by selectively eliminating an MHCII-Hi subpopulation of stromal macrophages that 
suppress HSPC growth.  Removal of these macrophages enables long-term HSC ex vivo stability 
and massive expansion of the MPP and its progeny.  Cultures expanded in this manner have 
increased engraftment potential and behave physiologically normal upon transplantation. 
 
This investigation has also helped to uncover the role of TGFβ in bone marrow quiescence 
signaling.  The MHCII-HI target cells express TGFβ and through it, signal quiescence to the 
HSPC, likely as a form of quorum sensing.  Targeted acute elimination of that signal leads to 
unabashed expansion of MPP. 
 Furthermore, macrophage polarization in the tumor microenvironment has also been show 
to promote tumor formation and often leads to poor prognosis. Molecular tools such as 999 that 
have the ability to alter macrophage polarization ratios may prove to be valuable synergistic tools 
for oncologists in conjunction with current therapies. 
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Stem Cells and the HSC  
The definition of "stem" cells are often topics of debate (Reaves, 2001) (Moore & 
Quesenberry, 2003). According to the  National Institute of Health (NIH): "All stem cells—
regardless of their source—have three general properties: they are capable of dividing and 
renewing themselves for long periods; they are unspecialized; and they can give rise to 
specialized cell types" (NIH, 2015a).  Embryonic stem (ES) cells have the capacity to give rise to 
all organs and tissues, a property known as totipotency.  In contrast, adult, or somatic stem cells 
have tissue-restricted differentiation capacity, or multipotency.  Adult stem cells maintain the 
self-renewal capacity of early embryonic stem cells, yet they persist throughout the span of our 
lives. Adult stem cells are present in a number of organs and tissues, including, but not limited to 
skin, gut, bone marrow, peripheral blood, ovarian epithelium, and testis (NIH, 2015b).  
Hematopoietic stem cells (HSC) are tissue specific stem cells that give rise to all other blood cells 
through hematopoiesis. (Smith, Weissman, & Heimfeld, 1991) 
HSC perform a multitude of tasks over the course of our lifetimes. During development 
and growth, they must first expand many times over to give rise to all of the cellular components 
of blood. HSC must also respond to environmental challenges, such as blood loss and infection. 
Upon reaching adulthood, HSC alter their chief program significantly, to the upkeep of 
homeostasis.   
 HSC themselves spend 95% of their lives in a state of dormancy, quiescence, G0, or cell 
cycle arrest (Pietras, Warr, & Passegue, 2011). It is believed that this quiescence is a mechanism 
of preservation of stem-cell function (to prevent exhaustion) and of protecting DNA integrity 
(Orford & Scadden, 2008). However, fully differentiated blood cells demand constant 
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replenishment, as their live spans range from as short as a few hours to a few months.  Somehow, 
a precise balance between the task of self-renewal and replenishing the body's hematopoietic 
system is struck to the tune of 200 billion red cells, ten billion white cells, and 400 billion platelets 
per day, every day. (Britannica, 2016) (Britannica, 2016)   
This seemingly paradoxical scheme is made possible by the middlemen: multipotent 
progenitors (MPP). Unlike HSC, MPP spend the majority of their existences actively dividing in 
order to do the heavy lifting of hematopoiesis. MPP do not self-renew indefinitely and instead 
have limited life spans of around six weeks (Fisher, 2012).  HSC enter the cell cycle in order to 
replenish exhausted MPP, implying the existence of some sort of regulatory system responsible 
for directing the HSC to enter and exit cell cycle.  In this way, HSC and MPP share the overall 
burden of hematopoiesis and it is common to collectively refer to them as hematopoietic stem 
and progenitor cells (HSPC).  Recent studies however, have identified intrinsic biases of single 
cells in sub-populations of HSPC previously considered homogeneous (Cabezas-Wallscheid et al., 
2014).  Such cells have the potential to give rise to either lineage given powerful enough 
stimulation but if left to their own programs, would stick to their pre-determined fate.  Cells such 
as these are beginning to reshape the way the field views the traditional hierarchy of the 
hematopoietic system (Figure 1). 
In humans, HSPC reside, primarily, in the bone marrow. Bone marrow (BM) can be divided 
into three main parts: red marrow, yellow marrow, and stroma. HSPC are considered a 
component of the red marrow, or hematopoietic tissue, where production of red blood cells, 
platelets, and many white blood cells takes place. HSPC were later found in peripheral blood and 
then in cord blood (Kessinger, 1986) (Gluckman, 1989). 
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 The first human bone marrow transplant was attempted in 1956 by Dr. Donnall Thomas 
(Thomas, 1957). At the time, in fact, it was not known that HSC are the working component of 
the bone marrow transplant; it would be another twenty years before the physical isolation of 
an actual HSC was achieved (Civin, 1984). The concept, however, of the HSC can be traced to the 
early 1960s when McCulloch and Till observed colony forming cells extracted from bone marrow 
and concluded that those cells were clonogenic (Till & McCulloch, 1961).  Indeed, for decades 
following, in vitro colony forming units (CFU) were the de facto quantification metric for HSC 
frequency(Lowenberg & Dicke, 1977).  Later, cobblestone formation, named after the 
morphological appearance of the cultured cells themselves would further improve specificity in 
studies where transplantation may be too difficult (de Haan & Ploemacher, 2002).  Modern 
technologies have since evolved – single cell characterization and isolation techniques most 
notably widespread use of fluorescence activated cell sorting (FACS) enable today’s scientists and 
clinicians to identify and isolate HSC or MPP subpopulations from tens of millions of cells in less 
than an hour.  The power of the HSPC has been realized and peripheral blood stem cell 
transplantation (PBSCT) is the most common transplantation procedure performed in medicine 
(Körbling, 2011). 
 
HSC in the Clinic 
 For over 30 kinds of cancer, congenital and autoimmune diseases, hematopoietic stem 
cell transplantation (HSCT) is considered either the standard of care, or at least a clinical option. 
For still dozens more, HSCT therapy is currently under development (CIBMTR, 2015). For 
example, HIV infection of MPP is under investigation as a mechanism of persistent infection 
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(Zhang & Crumpacker, 2010). Successful HSCT outcomes for MS patients have been reported in 
just the past five years (Burt et al., 2015; Kyrcz-Krzemien, Helbig, Torba, Koclega, & Krawczyk-
Kulis, 2016). Does any other single treatment have the potential to treat, and even to cure, such 
a breadth of disease? 
 As organ transplantations go, HSCT is wildly successful.  When HSCT fails, it is either 
because HLA-matching between donor and recipient was inadequate or the number of HSC 
transplanted was insufficient to adequately repopulate the hematopoietic system.  Most patients 
must rely on registry matching as only 30% of patients are able to find familial matches. (NMDP, 
2016) Even amongst these, incompatibilities still occur.   The best match is obviously within the 
patient’s own BM, and a self-renewing cell such has the HSC should theoretically be able to be 
expanded ex vivo and transplanted back into the patient with perfect compatibility.  Until this is 
a reality, stem cell therapy relies on either a bone marrow donor or cord blood transplantations 
to achieve sufficient numbers of HSC.  This too however, is limited by HSC availability.  Umbilical 
cords obviously contain fewer cells than a fully grown adult, just as a donor will certainly not 
donate the entire contents of their bone marrow.  Engraftment success correlates directly with 
the amount of input HSC(Cutler & Ballen, 2012; Futrega, Lott, & Doran, 2016);  pooling multiple 
sources (eg >1 cord) may increase the chance of engraftment but also the odds of graft rejection.  
Expanding HSC for transplantation provides tremendous value yet few therapeutic options have 
been introduced, all of which appear to stall before making it all the way to the clinic. 
 The copper chelator StemEx® completed  its Phase 3 trial in June of 2015(Gamida Cell -
Teva Joint Venture, 2013). Although the trial was considered successful, when the company 
submitted the product for approval from the US Food and Drug Administration (FDA) they asked 
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for another trial.   The company considered investing in another trial not to be worthwhile, and 
development of the product was halted (Weinreb, 2015). 
 In preclinical studies, the aryl hydrocarbon receptor antagonist StemReginin1 (SR1) was 
found to promote expansion of CB CD34+ cells that contribute to both early and sustained 
engraftment in murine models (Boitano et al., 2010).  There are two currently recruiting Phase 1 
and 2 clinical trials for SR1.  Novartis, the trials’ sponsor, report that SR-1 expansion trials 
improved neutrophil and platelet recovery compared to controls but make no claims of HSC 
expansion.(Novartis & Novartis, 2017; Wagner et al., 2016) 
  Prostaglandin E2, first discovered in zebrafish(North et al., 2007) climbed its way as a 
therapeutic up the evolutionary chain through mice and monkeys(Goessling et al., 2011) but after 
completing its Phase 1 trial in 2013, for various reasons the investigators deemed the study 
largely inconclusive. (Fate & Dana-Farber Cancer, 2013) (Cutler et al., 2013) 
 Notch-mediated expansion has also been proposed, a Phase 1 trial completed in 
2015(Fred Hutchinson Cancer Research, National Heart, Blood, National Cancer, & Damon 
Runyon Cancer Research, 2013) reported initial success by co-transplanting expanded cord blood 
with unmanipulated cells for support, but by 1 year, the donor engraftment proved to be 100% 
from the unmanipulated cord blood graft. (Delaney et al., 2010) According to a paper published 
in 2013, (Horwitz et al., 2013) there is an ongoing Phase 2/3 Notch 1 clinical trial at the Fred 
Hutchinson Cancer Research Center in Seattle, but as of this writing, no such trial could be located 
on the FHCRC’s own clinical trial search engine or clinicaltrials.gov.  
 Chemicals to increase HSC growth ex vivo provide additional value as they can easily be 
removed after HSC expansion. However, even fewer have been discovered that maintain HSC 
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function upon transplantation in vivo.  NiCord® has been the most successful ex vivo expansion 
intervention to date, at least in terms of being furthest along the therapeutic pipeline.  NiCord is 
an ex vivo expansion technique in which HSC are grown in vitro with heavy cytokine support and 
nicotinamide is added to inhibit differentiation. 
 
HSC in the Laboratory 
Blood, being a liquid organ,  has proved significantly easier to work with than solid tissue 
and as such, the HSC became one of the best characterized adult stem cells (Weissman, 2000).  
Because peripheral blood can be easily and painlessly drawn, obtaining primary tissue for 
hematopoietic research is quite non-invasive.  Once collected, blood and even bone marrow (BM) 
also require very little manipulation to isolate cells; solid tissue dissociation is not required and 
single cells are highly amenable to analysis or sorting by flow cytometry.  Despite their rarity, 
(1:10,000 cells in the BM) isolating reasonable numbers of HSC by FACS is done routinely and has 
become standard practice in the field (Ema, 1990; Weissman, 2000).   
 Despite the relative ease of isolating primary HSC, the cells have proven themselves to 
be fundamentally challenging to grow in the lab. Close to 70 years since the first deliberate 
attempts to grow HSC, we have only glimpsed their extraordinarily complex regulatory system.  
Tightly regulated cells like HSPC have been reported to receive signals from macrophages (Hur et 
al., 2016), megakaryoctyes (Bruns et al., 2014), osteoblasts (Park, 2012) osteoclasts (Mansour et 
al., 2012), adipocytes (Naveiras et al., 2009), and countless others.  Some of these signals come 
from the hematopoietic lineage itself, while others come from other cells in the BM 
microenvironment.  Several factors have already been identified as cues to stimulate HSC growth 
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(Majka, 2001). Chief among them, stem cell factor (SCF, also known as KIT-ligand, or steel factor) 
is an in vivo pro-proliferative cytokine (Langley, 1993; Ogawa, 1991; Zsebo, 1990).  By over 
expression or genetically knocking out signaling molecules, we have identified several other 
cytokines involved in in vivo fate specification during differentiation. Interlukin-3 (IL3) stimulates 
MPP to generate more myeloid cells while IL7 tips the balance in favor of new lymphocytes (Seita 
& Weissman, 2010). 
 Exogenous addition of pro-proliferative cytokines like SCF causes robust expansion of 
HSPC in vitro (at the expense of HSC – Chapter 2) and is necessary for the proliferation of many 
immortalized hematopoietic cell lines but also causes an acute exhaustion of stem cell function 
in primary HSPC (Holyoake, 1996; Orford & Scadden, 2008).  This appears to be a direct result of 
the expansion itself.  Knockout studies of p21, – a cyclin-dependent kinase inhibitor, show that 
increased HSC proliferation comes at the cost of exhaustion; as expanded HSC exhibit a loss of 
stem cell function (transplant ability) (Kippin, Martens, & van der Kooy, 2005).  Other cytokines 
are essential for the differentiation of various blood lineage cells. Thrombopoietin (TPO) for 
example, is necessary to generate new platelet forming megakaryocytes from HSPC derived 
myeloid-erythrocyte progenitors (MEP) (Kaushansky, 1994), but the same progenitor cell would 
produce erythrocytes if exposed to erythropoietin (EPO) (Miyake, 1977).  
 
Simplification vs Physiological: Pros & Cons 
 Perhaps the ability to easily isolate and work with HSC has resulted in a misplaced belief 
that a simple signal or single cell has this ability when in reality the system is much more 
 9
complicated.  There has long been a drive to isolate and remove unknown variables in scientific 
research.  Famous pioneering medical discoveries often involved what would be now considered 
primitive technical practices. Animal models are now inbred to the point of near identical 
genetics.  Standardized cell lines grown in nearly exactly the same conditions are clones of the 
same line used around the world. Yet nearly all mammalian in vitro cell culture still relies on 
largely unknown essential proteins from highly variable whole animal serum.   
 Despite this push to feeder-free culture, most stem cell research in particular still 
requires feeder layers of support cells that supply a multitude of unknown signals essential for 
survival of the target cells.  An entire industry has evolved around synthetically recreating natural 
conditions in a controlled and reproducible manner from serum free media supplements to 
recombinant signaling proteins.  Simultaneously, a push toward organotypic modeling is 
beginning to recreate complex organ systems using these synthetic standardized signaling 
programs(Jang et al., 2013) to accurately and consistently model what just a few decades ago 
could only be investigated superficially and inconsistently (Huh, 2010).   
 Our aim was to find unknown compounds that would increase hematopoiesis; 
throughput, consistency and ability to administer the compounds were of high priority.  In vivo 
modeling systems do not lend themselves well to any of these qualities.  Simultaneously, what 
works with extreme precision and reproducibility in overly simplified models can fail when 
translated into real physiology. It is likely here that previous HSC screens have failed to 
sufficiently recapture unknown environmental signals and why many promising therapeutics 
seem to fall apart during clinical trials.  Somewhere between immortalized cells lines grown in 
fully characterized conditions and a true in vivo animal model is a Goldilocks-style condition.  
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Given the current state of the field, we suggest that for bone marrow this balance is currently 
found in bulk organotypic cultures.  Whole marrow/HSPC co-culture allows consistent high 
throughput iteration and reliable administration of compounds while still maintaining much of 
the bone marrow’s microenvironment. 
 Many stem cells have an obligatory dependence on a niche or support cells in their 
microenvironment, and HSC are no exception (Li, 2005; Scadden, 2006).  Fifty years ago, Bradley 
and Metcalf reported that the growth of bone marrow varied based on the type of feeder cell 
layer used for in vitro expansion (Bradley, 1966). The significance of the microenvironment is 
further evidenced by the fact that when HSC are removed from the BM and cultured in vitro, they 
rapidly lose their stem-ness as measured by ability to successfully engraft. (Broxmeyer, O'Leary, 
Huang, & Mantel, 2015) For the next 50 years, finding a specific HSC niche cell or niche signal – 
one that provides live support the HSC has been one of the popular and prolific subjects in HSC 
biology.  Indeed, just within the last few years, several dozens of various cells have been proposed 
as HSC niche cells (Yu & Scadden, 2016).  We know that the HSC lives in the BM so not surprisingly 
most of these studies focus on mesechymal cells (Park, 2012).  
 Similarly, when HSC are taken from the same original colony to be grown separately in 
distinct microenvironments, they begin to behave significantly unalike one another, yet their 
differences consistently correlate with their new microenvironment (Wolf, 1968). For example, 
HSC cultured in splenic stroma favor the growth of erythroid colonies, while HSC cultured in bone 
marrow stroma favor production of more myeloid colonies. Hence, geographic location reveals 
itself to be high on the list of regulatory dimensions of hematopoiesis (Trentin, 1971).   
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 Thus, a full understanding HSC regulation requires deciphering the mechanisms by which 
the microenvironment signals the HSC to transition between varied states of self-renewal, 
quiescence, differentiation, and apoptosis.  Knowledge of these complex regulatory signals, will 
undoubtedly lead to a greater understanding of the underlying cellular biology and has a 
multitude of therapeutic applications from drug discovery to cellular therapeutics, and from 
regenerative medicine to oncology.  
 
Bone Marrow Macrophages 
 One of the cells in the hematopoietic microenvironment known to produce a wide range 
of cytokine and chemokine signals is the macrophage.  Macrophages are found in all organs of 
the body and in peripheral blood as monocytes, and they perform a wide variety of functions. 
Though we commonly think of the macrophages of the immune system, recruited in response to 
extracellular pathogens, there is a second major category of macrophages.  Tissue-resident 
(histocyte) macrophages perform a wide range of environmental functions in various organs from 
the Kupffer Cells that regenerate the liver to the microglia that make connections between 
neurons in the brain.  These histocytes, originally thought to have arisen from mesenchymal cells, 
are present throughout the body and provide support to nearly every organ system.  Although 
van Furth, Cohn and colleagues proposed in the 1960's that these cells might all rise from 
hematopoietic progenitors, it was not until widespread use of monoclonal antibodies in the 
1980's that these very distinct cells from completely separate organs were more definitively 
shown to have similar properties and likely similar origins (Hume, 2006). 
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 In the BM, monocyte and macrophage production is stimulated by the discerningly named 
macrophage colony-stimulating factor (CSF-1, also known as M-CSF) or granulocyte macrophage 
colony-stimulating factor (GM-CSF) (Stanley, 2009). Monocytes produced in the BM from myeloid 
progenitors can be either “classically activated” by interferon-gamma (INFg) or as discovered in 
the 1990's “alternatively activated” by IL-4 (Nathan CF, 1983; Stein M, 1992). Monocyctes, as well 
as the macrophages they give rise to, express very different transcriptional profiles based on their 
mode of activation and perform different functions.   
 Classically activated macrophages are commonly referred to as “M1” macrophages based 
on their relationship with the INFg producing T helper type 1 T cells (Mills CD, 2000).  These cells 
notably express high levels of major histocompatibility complex class II (MHC-II) and other surface 
markers (Duluc et al., 2007) and secrete large amounts of inflammatory cytokines, stimulating a 
robust immune response locally - particularly against bacterial infection (Schroder K, 2003).  The 
alternatively activated macrophages are in turn referred to as “M2” or “anti-inflammatory”.  This 
subset of macrophages performs tissue maintenance, removal of apoptotic cells, and promotes 
cell growth although these functions are likely performed by individual further subpopulations (S 
Gordon, 2003). Indeed, shortly after their discovery, researchers began compartmentalizing 
these M2 macrophages into subtypes each with distinct surface markers and expression profiles 
(M2a, M2b, M2c, M2d) (Colin, 2014). 
This neat organization has come under question in recent years (Stout et al., 2005).  It is 
now beginning to be appreciated that as more sub-classifications emerge, these distinctions blur 
and M1/M2 polarization may be better conceptualized as a spectrum of expression rather than 
a series of distinct baskets (S. Gordon & Taylor, 2005; Mosser & Edwards, 2008). New “subtypes” 
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of BM resident macrophages continue to emerge following particular paracrine signaling that do 
not align with previous classifications (L. Chiossone, Conte, R., Spaggiari, G.M., Serra, M., Romei, 
C., Bellora, F., Becchetti, F., Andaloro, A., Moretta, L. and Bottino, C, 2016) and individual cells 
show remarkable plasticity when cultured in vitro, changing polarization states dynamically in 
response to environmental changes (Davis et al., 2013). It would appear that like myeloid or 
lymphocyte biased HSPC, macrophages are highly susceptible to environmental signaling, and 
can experience significant fate shifts in order to maintain homeostasis in the BM. 
 This concept is not lost in cancer research.  Tumor associated macrophages (TAM) are a 
subset of “M2-like” macrophages that are recruited to the site of a tumor by cytokines and 
chemokines secreted by the tumor itself; they prevent the body's immune system from 
infiltrating it (Kitamura, 2015). High quantities of TAM in the tumor promote growth and 
vascularization as well as metastasis, and are often associated with poor prognosis in patients 
(Komohara, 2014). Re-polarizing TAM into a more “M1-like” state is gaining traction as an 
immunotherapeutic synergy therapy to assist current anti-cancer treatment. This approach turns 
a malignant microenvironment that favors the growth of a tumor into a healthy one that 
maintains proper physiological signaling (Mills, 2016). After all, even if we are able to successfully 
and completely treat a patient’s cancer, if we leave behind a poisoned, tumor promoting 
atmosphere, that patient is sure to relapse. 
 Within microenvironments, both healthy and malignant, we continue to find signaling 
paradigms. The rarity of primary HSC, difficulty in maintaining them, and the wide-reaching 
potential benefits of having massive HSC stocks both for research and clinical use have prompted 
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dozens of recent studies searching for techniques to increase HSC proliferation or signals from 
various cells 
 
Where are we Now? 
Routine HSC transplantation, even down to single-cell resolution in model organisms, is 
now possible.  Cells are easily injected intravenously (IV) into cogenic irradiated recipient hosts 
(mice in this case) and are able to give rise to an entirely new hematopoietic system in just a few 
weeks (Benveniste, 2003; Drygalski, 2005). Hosts must be irradiated to clear the majority of their 
existing immune system, in order to accommodate the new graft.  The relative ability of injected 
cells to repopulate the bone marrow gives the researcher a direct readout of the functional 
capability of those cells.  This measure of “stem-ness” is obviously a valuable parameter for stem 
cell research, but can also be a very important metric in the clinic as human HSC can be 
xenografted into immunocompromised mice (Shultz et al., 2005) following chemical or genetic 
treatment. 
 A self-renewing HSC gives rise to additional HSC, therefore when a single HSC is 
transplanted into a new host it has the ability to create an entire hematopoietic system consisting 
of cells from all lineages.  Included of course, are additional new HSC originating from that single 
cell of origin.  In contrast, a single non-self-renewing multipotent cell, when similarly 
transplanted, would still seemingly give rise to the various blood cell types but importantly would 
lack additional multipotent cells.  The only way to distinguish between these two situations is to 
transplant cells once again.  An HSC derived graft will have the capacity to engraft a second time 
as it still contains more HSC; a non-HSC derived graft will fail.  This serial transplantation 
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technique is the gold standard to define a functional HSC (Atala, 2011).  There are technical 
limitations to this, however, as it is extremely difficult to ensure that exactly one cell is 
transplanted.  The Limit Dilution Assay (LDA) utilizes probabilities to transplant large numbers of 
hosts with small, but non-singular quantities of heterogeneous cell populations (Ploemacher R., 
1991).  Some transplants will engraft and some will not as they do not each contain an HSC; the 
percentage of successful engraftments correlates with the frequency of HSC in the original 
heterogeneous population. While this technique cannot identify a single cell as an HSC, it can 
distinguish an HSC-enriched population from a non-enriched one. 
 Both the serial transplant and the limit dilution techniques rely on the ability of the 
researcher to distinguish graft cells from host cells.  With capabilities like flow cytometry and 
modern animal models, this task has become relatively simple.  The leukocyte antigen CD45 is 
expressed on nearly every hematopoietic cell in the body.  Two functionally identical isoforms 
are commonly found in inbred mice strains (CD45.1 and CD45.2).  The SJL mouse strain is identical 
to the common C57BL6 strain except that every leukocyte expresses CD45.1, while C57BL6 mice 
express CD45.2.  By selecting the cogenic SJL mouse as a host and transplanting cells from C57BL6 
strains, we can easily distinguish the two by staining for those two surface markers (Shen, 1985). 
 In research, we can determine the functional prowess of an HSC by its ability to engraft 
into a host.  Any modifications to the cell or cells that improve the engraftment frequency are 
said to have enhanced stem cell function.  Patients of course, cannot rely on a “slightly improved” 
chance for successful engraftment, their lives quite literally depend on it.  In the clinical setting 




 Immunotherapy and hematopoietic stem cell therapeutics are a rapidly growing field of 
biotechnology.  Recent advances in genomic editing (Hsu et al., 2013) have the potential to 
harness the hematopoietic system’s regenerative strengths and supercharge the immune system 
to fight previously incurable diseases (Maus & June, 2016).  These exciting new therapeutics 
however, still require improvements to current standard practices.  We need to maintain cells ex 
vivo for extended periods of time to reprogram them, and we need to reduce transplantation 
failures to actually administer cellular therapies to patients. 
 To be a viable long-term solution without unintended consequences, it is imperative to 
not only recognize what a cell can be coerced into doing in the short term through stimulation 
but how to maintain its full breadth of function for the lifetime of the patient.  After all, a single 
HSC may be able to give rise to an entire hematopoietic system; but physiologically, it has to do 
more than simply multiply or it is little better than leukemia.  Properly regulated HSPC will detect 
a need for new tissue, make that tissue, and return to a sustained level of homeostasis.  A full 
understanding the HSC lifespan thus requires deciphering the mechanisms by which the micro-
environment signals the HSC to transition between varied states of self-renewal, quiescence, 






















When we began looking for molecules to increase HSPC growth in vitro, we first had to 
re-create the organotypic bone marrow to recapture the physiological microenvironment of the 
HSPC.   Culture systems that do not adequately recapture this microenvironment fail to preserve 
the signals necessary to maintain HSPC function, primarily self-renewal of the HSC.  In the past, 
single cell culture screens, that is, with no secondary support cell, have relied on the presence of 
cytokines to maintain HSPC ex vivo. Still others have attempted to use immortalized cell lines as 
a “feeder cell” to lend in vitro support to the cultured HSPC.  Our novel organotypic co-culture 
screen preserves the natural bone marrow physiology necessary to maintain niche-regulated 
stem cell function of the HSC.  In doing so, we found a small molecule (999) that when added to 
this co-culture significantly expands total hematopoietic outgrowth of HSPC from the MPP to 
mature blood thereby enhancing HSC transplantation efficiency. 
 
Results 
 We investigated both exogenous cytokine support and feeder cell co-culture and found, 
as others, that while cytokine support generated a robust expansion of HSPC, those cells rapidly 
lost their self-renewal capability (Chapter 1).  When we begin this study, the OP9 cell line was 
commonly used as a support cell for the HSBC.  As with direct cytokine support, we found this 
cell line to be inadequate in maintaining stemness ex vivo.   
 It became readily apparent that the ideal way to re-create the bone marrow as an 
organotypic culture was to use primary bone marrow itself. (Figure 2-1a)  The current literature 
at the time suggested either bone forming osteoblasts or endothelial cells supported HSPC 
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growth (Purton & Scadden, 2008) so to provide ourselves with the greatest potential to expand 
HSPC we enriched stromal cultures by selecting for cells which expressed Endoglin (CD105), 
reportedly expressed on both cell populations.   Indeed, HSPC co-cultured with CD105+ cells 
expanded significantly more in culture than HSPC co-cultured with bulk non-enriched stroma, 
and far more than with the OP9 cell line (Figure 2-1a).  It should be noted however, that this 
positive enrichment process is imperfect and following selection, some adherent CD105- cells 
remain in culture.  
 By simply crushing the long bones of the mouse and filtering bone fragments out, we 
were able to liberate all of the cells contained within the bone marrow in their entirety.   We 
hypothesized that the non-adherent fraction of the culture contained many cells that were not 
essential in providing HSPC support and selected bone marrow culture outgrowth based on its 
adherence to tissue culture surfaces over multiple passages.  We cultured the remaining cells in 
vitro and observed distinct morphological changes in the culture of overtime. After three days of 
culture, small round cells began to adhere to the growth surface, while the vast majority did not.   
The large quantity of non-adherent cells rapidly consumed the nutrients in our culture media so 
we removed them after the three day adherence window. 
 Over the next seven days of culture, those adherent cells would expand and begin to 
form colonies. After 10 days of in vitro culture, extracted cells were approaching full confluence 
and many, but not all, of these cells began extending “fibroblast-like” cytoplasmic extensions.  
We observed heterogeneous stroma at this stage to double approximately every three days.  By 
day 13, this subset of cells had become significantly more asymmetric.  Primary stroma cultures 
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maintained the ability to double once again over three more days but after four passages, the 
cells began to senesce, detach and die (Figure 2-1b). 
We designed a small molecule screen to find compounds that would expand HSPC 
outgrowth in ex vivo culture. We defined our input HSPC for this screen as LKS CD48- (Chapter 
1). To obtain total counts of HSPC outgrowth and to distinguish those cells from this stromal 
monolayer, we incorporated a two color fluorescence system and captured the output with high 
throughput fluorescence microscopy.  Stromal cultures were generated from transgenic mice in 
which green fluorescent protein (GFP) was driven by the constitutively active beta-Actin 
promoter.   From these mice, every cell in our bone marrow culture is fluorescent in the GFP 
channel.   HSPC were similarly harvested from transgenic mice expressing the red fluorescent 
protein, dsRed, from the same promoter.    Buy co-culturing these two fluorescent cell types in 
the same well we were able to maintain stromal support in direct contact with the HSPC and still 
de-convolute the cells by imaging each fluorescent channel independently to determine total 
cellular outgrowth originating from “red” HSPC (Figure 2-2a). 
HSC co-cultured on a monolayer of this stroma maintain the ability to differentiate into 
all hematopoietic lineages, and maintain self-renewal capacity such that they are able to engraft 
into host mice after a short term (<3 days) ex vivo culture (Figure 2-2b).  After >3 days however, 
HSPC begin to bias toward myeloid progenitor cells (GMP) (Figure 2-2c).   We observed that 
primary stromal cultures required at least 2-weeks of in vitro growth to mature into niche-
forming support cells but as stated begin to senesce shortly thereafter.  We therefore elected to 
grow these cultures at 33°C rather than the physiological 37°C to broaden this window and 
prevent stromal overgrowth over the duration of the co-culture period.  
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 One day after mature GFP+ stromal cells were plated in the assay plate, dsRed+ HSPC 
were isolated by fluorescence activated cell sorting (FACS) and added to the assay.  Co-cultures 
were allowed an additional 8-12hrs to stabilize before arrayed addition (1 compound/well) of 
small molecules (20uM) in triplicate (Figure 2-3a). Vehicle only controls were also randomly 
present on each screening plate.  The small molecule library used was obtained from the high-
throughput screening facility at The Broad Institute and consisted of 17,280 small molecules 
nominated to the biological platform containing: Kinase-biased, Commercial Available, DOS, 
Bioactive, Natural Product, and Chromatin-biased collections (Figure 2-3b). 
Co-cultures were grown in presence of small molecules and after five days of outgrowth, 
assay plates were autofocused and imaged by high-throughput fluorescence microscopy (Figure 
2-4).   GFP and dsRed channels were captured as full well images in this manner to not only obtain 
total outgrowth numbers but also obtained information regarding the differentiation status of 
HSPC progeny by morphological changes, as well as co-localization between hematopoietic cells 
and stromal support for later analysis. 
 Images were automatically converted to binary as described; (Materials and Methods) 
GFP images were scored as Pass/Fail by criteria that >30% of the well surface must be covered 
by above threshold GFP signal (live cells).  Compounds that “fail” were considered toxic to stroma 
and were removed from further analysis.  DsRed images, once converted to binary, were counted 
using the “analyze particles” function in ImageJ.   This high throughput screening method allows 
us to capture total absolute cell counts of hematopoietic outgrowth from thousands of wells.   
Due to the extremely large numbers of HSPC required for a screen of this magnitude and 
the relative rarity of the cells in the bone marrow, this screen was run over seven separate 
 23
instances.  Compounds from multiple (but not all) libraries were run in each instance and 
variability was comparable between iterations.  Vehicle mean and standard deviations for each 
screening session were calculated and total cell counts were represented as Z Scores.  Of 17280 
molecules tested, 42 were found to increase HSPC outgrowth in the co-culture setting (Z>3).  
These hits were rerun for validation and 18 were confirmed to expand total HSPC cellular 
outgrowth.  Total cell growth normalized to vehicle control shows that compounds from all six 
libraries hit under these criteria (Figure 2-5a). 
  Four top hits from the screen were rerun in 4-point doses (2-20uM) with 12 replicates 
each. (Figure 2-5b) Co-culture expansion following treatment responded in a dose-dependent 
manor for all four compounds.  Although four compounds exhibited consistent dose response, 
only one would prove to maintain stem cell function.  
If a hit compound does not alter hematopoietic potency, we expect that HSPC expanded 
in this manner should still give rise to all hematopoietic lineages and at normal ratios to each 
other.  HSPC, MPP, lineage specific progenitors, and mature lineage committed cells should also 
exist in physiological proportions if we are to claim this screen is organotypic.  Indeed, just as 
simply co-cultured HSPC maintained phenotypic endogenous hematopoiesis assessed by flow, so 
too do HSPC additionally expanded by treatment with the hit compound 999. (Figure 2-6) 
To determine if HSPC expanded in co-culture and treated with these four compounds 
maintained any self-renewal capacity, we harvested and pooled the total outgrowth of 10 wells 
(3000 input cells) treated either with compound, vehicle alone, or stem cell factor (SCF).  SCF was 
used because we knew that it expanded cells in vitro, but those cells do not maintain self-renewal 
capacity upon transplantation. The outgrowth of these 3000 cells were injected into a single 
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lethally irradiated cogenic SJL recipient host by tail vein (n=9 mice per treatment). Each injection 
was co-injected with 1 million bulk freshly-isolated nucleated bone marrow cells from C75/B6 
donor femurs as competitors to quantify transplant competence of the expanded cells and to 
maintain hematopoietic support in the immunocompromised host.   
Mice were returned to their home cages for four weeks to allow for engraftment of the 
injected cells, after which peripheral blood was drawn from the tail vein and chimerism was 
assessed by flow cytometry.  The ex vivo expanded HSPC, as in the screen, were derived from 
actin-dsRed mice and therefore fluorescently labeled. wt competitor bone marrow cells express 
the CD45.2 cell surface antigen, while expanded HSPC and native host cells both express the 
CD45.1 isoform of the same antigen.  Insufficiently irradiated CD45.1+ host cells are eliminated 
from the analysis. Chimerism corresponds to the percentage of CD45.2+ cells that are dsRed+  
(Figure 2-7a).  This analysis was repeated at 8 and 12 weeks post transplantation.   
One ex vivo treatment (compound: 999) resulted in not only in the in vitro expansion of 
total cells, but those cells maintained significantly improved engraftment potential over vehicle 
alone, as measured by chimerism after transplantation (Figure 2-7b).  Following 12 weeks of 
transplantation, bone marrow from the nine chimeric mice injected with 999 treated HSPC was 
harvested and analyzed by flow cytometry to determine if various blood lineages: b220+ b-cells, 
CD3+ t-cells, and gr1+ myeloid cells, existed at approximately the same ratios as unmanipulated 
cells (competitors).  It should be noted that this does not reflect any information about the 
composition of the progenitors or mature ex vivo outgrowth cells originally harvested and 
transplanted.  Those original mature cells would have not only reached the end of their lifespan 
and been turned over but are far too few in number to ultimately be detected. For example, over 
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the span of five days ex vivo, 3000 cells would expand to approximately 10,000 cells; this 
represents only ~0.002% of the bone marrow, the percentages we observe rather correspond to 
tens of millions of cells.  The observation that physiological ratios are maintained suggests rather 
that physiological multipotency in the expanded HPSC is maintained.  There does however appear 
to be a slight reduction in myeloid repopulation suggesting that the MPP has expanded while the 
HSC has been merely preserved (Figure 2-7c). 
In addition to this analysis, 500,000 bone marrow cells from primary transplant chimeras 
(pooled across replicates to normalize for inconsistencies) and 500,000 additional competitor 
cells were transplanted into secondary lethally-irradiated SJL host mice (n=5 mice each) to fully 
demonstrate self-renewal capacity (Introduction). HSPC expanded in the presence of vehicle 
alone or SCF were able to generate some MPP, such that when transplanted they gave rise to 
new blood cells in the first transplantation setting.  Upon secondary transplantation however, 
these cells failed to engraft a second time as they no longer contained any HSC following ex vivo 
culture.  In contrast, HSPC expanded in co-culture and treated with 999 were able to engraft 
serially over multiple transplantations (Figure 2-8a).  This secondary engraftment not only 
persisted throughout the entire additional 12 weeks, but the mature fluorescently labeled cells 
that grew out again maintained some multi-lineage potential. As with the primary 
transplantations, the myeloid compartment of these outgrown cells is reduced, again suggesting 
that expanded MPPs have given rise to a quick burst of myeloid cells while original dsRed HSPC 
were not expanded during ex vivo culture (Figure 2-8b). 
By performing complete hematopoiesis ex vivo, and simultaneously maintaining true HSC 
function we can create a “blood factory” in which a small quantity of input HSPC be grown over 
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long periods of time and generate large numbers of progenitors and mature blood cells of all 
lineages. While such a system does not have direct translational benefits for HSCT, lab grown 
blood could prove to be a useful way to generate large quantities of blood for transfusions and 
other applications.   We expanded just 2000 input HSPC in co-culture on stroma with 999 and 
were able to grow and expand those 2000 cells to 50 million (approximately the number in the 
entire murine bone marrow) over the course of 28 days. The number of phenotypic HSPC 
determined by flow cytometry (LKS, CD48-) cells that grew out were roughly the same number 
of HSPC in the mouse (Figure 2-9a).   While the number of HSPC expanded dramatically in culture, 
later experiments suggest this expansion represented growth in only the MPP (CD150-) 
population while the CD150+ population remained constant (Figure 2-9c).  
For technical reasons, the absolute numbers of CD150+ cells is difficult to assess.  As 
stated previously, stroma will begin to senesce and die after 20 days of culture. To perform long 
term co-culture experiments, HSPC outgrowth must be serially passaged onto new fourth-
passage (P4) 15 day cultured stroma every seven days.  Not all cells are transferred to conserve 
reagents (mainly available stroma) and total cell outgrowth is calculated as total cells x 
cumulative dilution factor.  Total number of sub-populations was determined by flow cytometry 
as a percentage of total cells.  Therefore, as cultures grew-out over time, a consistent population 
such as CD150+ HSC would represent a smaller percentage of the total cells, a smaller percentage 
of which was harvested for flow cytometry each passage. 
As with shorter term expansions, 14 day ex vivo culture preserved input HSC and 
maintained HSC functional capabilities, cells are even able to engraft at comparable efficiencies 
to similar numbers of freshly isolated HSC.  After 14 days of culture the total outgrowth of one 
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input HSPC (~5000 cells) was transplanted as described (Materials and Methods) and competed 
against 500,000 competitor bone marrow cells (n=10 mice) (Figure 2-9c).  Similarly, the total 
outgrowth of one input HSPC grown in co-culture treated with vehicle alone (~0 cells) was 
transplanted (n=2 mice); and 25000 freshly isolated bone marrow cells statistically expected to 
contain one HSPC (n=5 mice).  Despite this long term culture, the single HSPC cultured on 999 
treated stroma maintained similar engraftment efficiency to the freshly isolated HSPC.  Notably 




Long term cultures like these are not only valuable as a mechanism to generate support 
blood or to assist in bone marrow transplantation but as genetic engineering becomes more 
common place and techniques are improved, researchers will need to maintain lineage-
dedicated stem cells during ex vivo editing.  Current best practices for editing most primary cells 
involve either culturing the cells ex vivo or editing in a more primitive cell (that can be easily 
cultured) and differentiating it to the cell of interest.  Despite extensive efforts, in vitro 
differentiation of HSC from ES cells remains a challenge, as most attempts to do so have failed 
(Muller & Dzierzak, 1993). Once editing and selection techniques are optimized for primary non-
rapidly dividing cells, co-cultures treated with 999 may be an ideal platform to maintain HSC for 
genomic editing. 
Although we have demonstrated that 999 and stromal co-culture is a sufficient platform 
to expand hematopoiesis, HSC themselves notably do not appear to expand under these 
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conditions.  Nonetheless, the newly created cells do seem to grow at physiological proportions 
and after long enough ex vivo culture, tremendous growth is possible.  Furthermore, it may 
actually be preferable to leave the cultured HSC undisturbed to prevent undue strain or DNA 

































 The co-culture platform on which we conducted the previously described screen was 
unique from previously published HSPC proliferation screens because this was the first small 
molecule screen within the context of the mammalian BM niche.  As such, we were able to 
capture compound-induced changes to the microenvironment en masse.  We see time and time 
again that stem cells have an obligate dependence on their niche (Chapter 1; Appendix B), yet 
the scientific screening community continues to isolate these cells, support them artificially, and 
force them to behave in a manner unlike they ever would in vivo. This may explain why in vitro 
results often fail to translate to an in vivo setting.   
Not only is it important to find compounds that maintain efficacy when translating from 
HSPC in isolation to HSPC in its niche (ie not simply replacing niche factors removed by taking the 
niche cells away), compounds that act indirectly on the HSPC through the niche are even more 
helpful both academically and therapeutically.  Niche affecters help us deconvolute the complex 
signaling occurring in the microenvironment and the effect such signals have on the HSPC.  HSPC 
grown in a “primed” niche have a better chance of remaining genetically undisturbed and are 
less likely to suffer from exhaustion or mutations than HSPC artificially forced into rapid cell-cycle. 
999 is one such non-autonomous compound.  By altering the makeup of the co-culture 
microenvironment, it creates a primed niche that encourages hematopoiesis.  We further 
demonstrate that direct intervention on the microenvironment composition similarly alters its 





Our co-culture system relies on a complex unknown “feeder” monolayer of crushed long 
bone.  Like the pioneering studies of 60 years ago, we found that maintaining tissue in close to 
its physiological state to be the best way of controlling for unknown regulatory factors in the 
largely “black box” environment of the BM.  The shortcoming of this approach are lack of 
consistency across cultures and heterogeneous populations of starting material in our stromal 
cultures. We observed that many factors dramatically influence the final composition of stroma 
cultures; chief among them were: force of bone crushing, cell scraping technique, and time 
course of culture.  We attempted to control for consistency by using in-bred mouse strains 
harvested at a consistent age, and strictly following a precise time course for stromal preparation: 
mice were always sacrificed late afternoon on Wednesday, media change on day 2, first passage 
split 1:2 on day 10, second passage on day 13 with magnetic cell depletion/enrichment were 
applicable, third passage and finally plated for experiment on day 17.  We further attempted to 
control for the two procedural variables by having a single researcher (myself) consistently 
prepare all stromal cultures. 
 Our lab had recently published papers (Raaijmakers et al., 2010; Worthley et al., 2013) 
describing the powerful effect that a modified bone marrow can exert on the cells that inhabit it.  
Given that our compound 999 had not yet appeared in any of the several single cell screens 
conducted recently, we hypothesized that 999 may be having a non-autonomous effect on the 
HSPC, affecting the stromal culture rather than the HSPC itself.   
In our discovery experiment, both stroma and HSPC were exposed to 999 for five days.  
To investigate whether 999 was autonomous or not, instead, we treated a mature stromal culture 
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either with 20uM 999 or DMSO vehicle alone; and after three days of exposure, stromal growth 
media was removed from the assay and replaced with new naïve media, dsRed-HSPC, and 999 or 
DMSO respectively.  After three additional days, we counted total outgrowth of the HSPC with 
fluorescence microscopy as described in Chapter 1.  Ideally, we would expose stroma alone to 
999 and HSPC alone to 999, but HSPC cultured without stroma require significant cytokine 
support and would not be comparable.  Pretreatment of the stroma alone created a primed 
microenvironment such that HSPC added to pretreated culture grew as robustly as HSPC directly 
exposed to 999; additional concurrent treatment increased growth potential even further (Figure 
3-1a). 
This suggested that 999 may be affecting the stromal compartment in co-culture; it was 
however, it was also possible that removal of 999 from the system was incomplete and trace 
amounts of 999 left behind after replacing with fresh media were sufficient to elicit growth 
advantage directly on the HSPC.  To this end, we devised a time course experiment in which 
stroma alone was exposed to 999 for 0, 12, 24, or 72 hours prior to HSPC addition.  Again, cells 
were imaged and counted after three additional days of growth.  The outgrowth potential of the 
added HSPC increased directly with the duration of stromal exposure to 999, nearly doubling 
support capacity over co-culture alone following 72hrs of pretreatment, despite HSPC 
themselves being exposed to 999 for the same duration (Figure 3-1b). 
Taken together, these data strongly suggest that 999 increases the HSPC support capacity 
of BM stromal cultures rather than directly influencing the HSPC itself.  This support layer 
intentionally consists of many different cell types, several of which had not yet been well 
characterized.  We observed that following 72 hours of 999 treatment, mature stromal 
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composition was visibly altered (Figure 3-2a). While early passage stroma contained nearly all 
small, round cells, mature CD105+ enriched stroma contained on average ~50% small round cells 
and 50% large fibroblast-like cells, though this ratio varied between stroma cultures significantly.  
Following 999 treatment, stroma composition shifted significantly to favor these larger cells but 
individual composition of each particular stroma remained variable.   
This large/small cell dimorphism was easily de-convoluted by flow cytometry (Figure 3-
2b), which confirmed that the small cells contained a significant subpopulation of hematopoietic 
cells (CD45+).  All such cells were additionally CD11b-high and Gr1-low, characteristic of 
macrophages (Figure 3-2b). While magnetic bead CD105+ enrichment of the stroma was 
designed to remove most of these cells, it is known to be incomplete; we hypothesized that this 
was a major source of inconsistency in our experiments.  Indeed, non-enriched stroma cultures 
consistently contained 75-80% CD45+ and HSPC outgrowth was more consistently augmented by 
999 addition.   
 Three day 999 treatment of non-depleted stromal culture not only strikingly alters the 
proportion of small to large cells by gross observation, but also reduces the overall number of 
cells in the stroma. HSPC are able to be counted in their entirety buy our counting algorithm 
because they are consistent in size and shape.  The heterogeneous stroma does not offer us this 
luxury.  We measured overall cellular metabolism of the stromal culture by tetrazolium reduction 
(MTS).  A solution containing tetrazolium (Promega G3581) is added to actively growing cells in 
culture.  Live active cells reduce the tetrazolium to formazan over 1 hour which stains the wells 
a darker purple the more viable cells are in the well. A pulse of 490nM light is shown through 
each well using a fluorimeter and the amount of light absorbed by the dye is calculated, higher 
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absorbance corresponds to more live cells.  We observed that after three days of treatment with 
999, fewer cells remained; however, after only 24 hours of treatment however there was no 
change (Figure 3-3a). If a standard ladder is used, in which a series of known quantities of cells 
are plated and absorbance is calculated, a standard curve of reference absorbances can be used 
to back-calculate approximate total cells in the test conditions.  This method has three 
shortcomings for our use.  First, our cells are heterogeneous; some cells are more metabolically 
active than others and they grow at different rates.  Therefore, assigning absolute cell counts to 
absorbance values gives improper weight to more active cells.  Second, all the cells are growing 
over the three day treatment period, if we were to seed known quantities of cells at day zero, by 
day three, those number would be irrelevant.  Conversely, plating fresh known quantities of cells 
at the time of MTS addition may yield dramatically different reduction potentials.  Finally, 
calculations being several steps removed from actual true counts, we preferred a more accurate 
metric. 
 We elected to count cells in stroma culture using quantitative flow cytometry.  Stroma 
was plated at 30,000 cells per well (approximately 15,000 CD45+) and treated with 999 or vehicle.  
Cells were harvested from individual stromal cultures daily and resuspended for flow cytometry, 
stained for CD45 and a known quantity of uniform fluorescently labeled microbeads were added 
to each sample.  These beads can be distinctly and accurately detected from cellular events by 
flow cytometry and sample is collected until half beads have been run – this assures very close 
to half of the cells in the sample have been run well within a reasonable margin of error; 
attempting to run 100% of a sample directly in flow cytometry is problematic.  Counting cells by 
flow cytometry in this manner also allows us to assess total counts of subpopulations of cells, in 
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this case CD45+ stromal cells.  Over the span of the final four days of culture (days 17-20) these 
15,000 CD45+ input cells grew rapidly to well over 100,000 cells.  In cultures with 999 however, 
this population expanded only slightly (Figure 3-3b). CD45- cells did not expand significantly over 
this period in either treatment.  In addition to verifying that 999 retards macrophage growth and 
maintains stroma in a more CD45- state, this experiment also further confirms what we had seen 
in both the exposure timecourse and MTS experiments: three days of stromal exposure is 
desirable to get maximal effect from 999. 
AnnexinV is a cellular protein used to detect phosphatidylserine on cell surfaces, an event 
occurring during apoptosis.  AnnexinV staining is often accompanied by a nuclear stain such as 
7AAD or DAPI that cannot permeate live cell membranes but is able to gain access to DNA in dead 
cells.  We stained stromal cultures with AnnexinV and 7AAD after two, three, and four days of 
999 treatment and calculated dying cells within the CD45+ compartment.  999 treated cells were 
consistently under greater apoptotic stress than untreated cells, and as treatment duration 
increased, dead CD45+ cells accumulated in the 999 treated stromas (Figure 3-3c,d).  
We suspected that the CD45- subset of the stroma might be protecting the stromal 
macrophages from apoptosis.  We FACS sorted CD45+ cells from P3 stromal culture (stromal 
macrophages appear unique from bulk freshly isolated macrophages), and treated them with 999 
in isolation for three days.  Similar to full stroma culture, these cells treated in isolation express 
an approximate two-fold increase in AnnexinV and a slight ~40% increase in dead cells after three 
days.  Fortunately, the efficacy of 999 does not seem to be inhibited by non-target cells; this could 
prove to be important for long term “blood factory”-related applications where many cells are 
present in the co-culture. 
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If 999 kills macrophages in stromal culture, albeit with modest efficiency, and that stroma 
gains enhanced HSPC support capacity, surely complete removal of stromal macrophages should 
enhance that capacity even further.  We used two methods to purify our stromal culture: one 
mechanical (FACS) and one genetic.  Sorting CD45+ cells from mature stroma was as simple as 
isolating any other primary population; we simply stained mature stroma with CD45 fluorescent 
antibodies and collected the positive cells.  Collecting the CD45- population however, proved to 
be much more difficult than anticipated.  It is often difficult to distinguish cells lacking a positive 
selection marker from debris or dead cells, fortunately our two-color co-culture design ensured 
that all live cells would be GFP+; the CD45- stromal compartment therefore could be found within 
the GFP+ positive selected cells.   
More problematic was the size of the cells.  Recall that these stromal cells grow to nearly 
10 times the size of the macrophages after 2.5 weeks of culture.  FACS works by suspending each 
individual cell or “event” in a droplet of saline or “sheath”; these droplets are passed through a 
series of lasers and fluorescence values corresponding to the stained surface antigens are 
assigned to each event in real time.  If a given event’s values are within the gated range for all 
channels, that droplet is deflected by electrostatically charged plates and diverted from the 
stream of other events into the collection vessel.  The size of the droplet is determined by a small 
nozzle, set by the operator, larger nozzles suspend cells in larger droplets and require less 
pressure but run through the machine more slowly.  These very large CD45- stromal cells occupy 
most of the volume in their droplets, leaving very little space for sheath.  It is the ions in the saline 
that allow it to be deflected properly. These events contain insufficient sheath to generate 
enough force to deflect the droplets path from the ungated events; a problem further 
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exacerbated by the increased density and therefore mass of the cellular material in the droplet.  
Even the largest nozzle available (130um diameter) failed to appropriately separate these 
massive cells approaching 100um (Figure 3-2a). 
Recall that early passage stromal cultures contained only small cells.  CD45- cells were still 
present in the cultures (actually at higher frequency relative to macrophages than mature 
cultures) they were just much smaller.  By sorting stromal cultures at day 10 instead of 16 and 
culturing the two populations of cells independently for the remaining six days to maturity, we 
were able to overcome the sheath volume issue and generate mature stromal cultures, devoid 
of any macrophages.  HSPC grown on this purified stroma have a significant increase in total 
hematopoietic growth over the three day co-culture period compared to normal stroma culture 
(Figure 3-4a), but only to the same approximate magnitude as 999 treated heterogeneous stroma 
(two-fold). Furthermore, additional 999 treatment of sorted stroma did not yield any further 
expansion potential, confirming that the stromal macrophage is indeed the target of the 
compound. 
We have maintained that many cells in the bone marrow provide various signals to each 
other.  Culturing CD45- stromal cells for six days in isolation while they mature may be removing 
many of those essential signals that recreate our organotypic microenvironment.  In order to 
acutely remove stromal macrophages from culture, we prepared stroma from a transgenic 
mouse in which every hematopoietic cell expresses a toxin receptor not normally present on 
mouse cells.  CRE is a bacteria-derived tyrosine recombinase, in this case driven by the Vav 
promoter, which is active in early hematopoietic cells.  This mouse was crossed with a mouse 
carrying an inducible diphtheria toxin receptor (iDTR) located at the highly transcribed ROSA26 
 47
genomic locus; the gene is inducible because it is proceeded by two lox-p sequences flanking a 
stop codon.  The stop codon ensures that the gene is not normally expressed until CRE is present.  
In our Vav-DTR mouse, CRE recombinase is only expressen in hematopoietic cells and removes 
the stop codon between the two lox-p sites only in these cells. This recombination occurs at the 
genomic level, so once the cells have expressed Vav, they will continue to express DTR.  
Administering diphtheria toxin (DT) directly to these mice would kill at hematopoietic cells and 
in turn the mouse, however adding DT to stroma culture acutely kills all hematopoietic stromal 
cells.  We confirmed that all stromal hematopoietic cells were in fact removed from culture by 
flow cytometry (Figure 3-4b). Additionally added dsRed-HSPC do not express this receptor and 
are unaffected by the toxin.  This genetically-depleted stroma similarly recaptured the increased 
HSPC support potential seen in stromas with macrophages depleted by either 999 of FACS 
separation.  Interestingly, like mechanically purified stroma, the support advantage inferred did 
not exceed that of partial macrophage ablation with 999.  Also like FACS separation, CD45-purifed 
stroma was rendered immune to further augmentation by 999 (Figure 3-4c).  
Prior to DT ablation, this particular stroma contained about 40% macrophages and 60% 
CD45- cells.  After DT ablation, of course, there were none.  We added back wildtype stromal 
macrophages to purified stroma to recreate this endogenous 40% ratio and found that by 
restoring the ratio of macrophages to CD45- stroma, we lost the inferred support advantage for 
HSPC upon co-culture.  HSPC grown in this co-culture setting expanded similarly as if no 
manipulations had occurred.  Additionally, this physiologically restored microenvironment 
became once again sensitive to 999 treatment (Figure 3-5a).  Using this same method, we created 
stromas with a range of macrophage ratios from 0-100% and co-cultured them with HSPC.  We 
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found that support capacity of the stroma varied directly with the amount of macrophages in 
culture (Figure 3-5b).  This strongly suggests that stromal macrophages inhibit HSPC growth in 
vitro.  Why then does 999, which only removes some macrophages, confer the same HSPC growth 
advantage as complete macrophage purification? 
It is hardly groundbreaking that given time, macrophages overgrow in primary stromal 
cultures. Macrophage “contamination” is one of the main justifications for the push away from 
primary support cells.  Mesenchymal cells are known to secrete macrophage colony stimulating 
factor (CSF-1) (L. Chiossone et al., 2016) which stimulates the growth of macrophages in vitro; 
eventually outcompeting the rest of the stroma.  It is also reasonable that bone marrow 
macrophages should suppress HSPC growth since they are direct progeny of the HSPC; their 
presence may provide a quorum signal to the HSPC alerting that no further replication is 
necessary.  This may likely be one of the key reasons HSPC have proved so difficult to maintain 
ex vivo.  Few solutions exist to maintain bone marrow cultures in a macrophage-free state and 
none have become widely adopted (Introduction).  Where these solutions fall short, is their 
fundamental target. 
 To expand our findings, we attempted to acutely remove macrophages in vivo to see if 
we could recreate the in vitro phenotype and generate increased HSPC in the bone marrow.  The 
Vav-DTR was problematic as stated above so we used the same iDTR system driven instead by a 
myeloid specific promotor.  Lysozyme2 (LyzM) is expressed in monocytes, mature macrophages 
and granulocytes but not in HSPC of lymphocytes.  We crossed the LyzM-CRE mouse to the 
previously described iDTR mouse as well as iRFP as a reporter.  The resulting mouse should 
express DT receptor on RFP fluorescent myeloid cells while other cells were unlabeled and 
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insensitive to DT.  We harvested bone marrow from this mouse and treated with DT as we did 
with the Vav-DTR mouse, but we saw almost no difference in the number of CD45+ stromal 
macrophages after ablation (Figure 3-6a). In addition, we also saw many macrophages which had 
not undergone recombination and did not express RFP (Figure 3-6a). This demonstrated that this 
particular mouse model generated insufficient levels of recombination for our purposes; 
therefore, we elected to pursue an alternate ablation model.  In this alternate model a 
macrophage specific element directly drives DTR, requiring no recombination. 
 CD11b or integrin alpha M, is a surface antigen expressed on monocyctes, macrophage, 
granulocytes, and natural killer (NK) cells.  It is involved in phagocytosis, and so synonymous with 
macrophages it is also known as Mac-1 (Solovjov, Pluskota, & Plow, 2005).  CD11b-DTR/GFP mice 
express a DT receptor/GFP fusion under the control of the CD11b promotor.  Macrophages 
should be GFP+ and express DTR transiently. Unlike the LyzM model, only cells currently 
expressing CD11b will fluoresce and express DTR.  We administered DT to these mice over five 
days, as well and once again discovered no change in bone marrow HSPC.  We also did not 
observe any GFP signal in these mice by flow cytometry as the authors originally describe (Burnett 
et al., 2004) with or without DT ablation.  Interestingly, while F4/80+Cd11b- cells were slightly 
decreased, CD11b+ cells were not only still present in the bone marrow of these mice following 
administration of DT, but had actually increased (Figure 3-6b). The Jackson Laboratory has 
recently updated their description of this mouse model to reflect their in-house findings that 
confirm our results regarding this mouse model (Jackson, 2016). 
 There is in fact, a working macrophage ablation mouse available. Recall that CSF1 
stimulates macrophage growth.  Macrophage associated Fas-Induced Apoptosis (MaFIA) mice 
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express mutant human FK506 binding protein 1A, driven by the CSF1-receptor.  When this 
protein binds the dimerization drug AP20187 it induces apoptosis in the cell.  We administered 
AP20187 to these mice via three IV injections over five days.  24hrs after the final injection, mice 
were harvested and bone marrow was analyzed by flow cytometry.  We observed a significant 
reduction in bone marrow macrophages in vivo following MaFIA ablation (Figure 3-7a).  Gr1-high, 
F4/80- granulocyte cells also express CSF1 receptor, are sensitive to MaFIA ablation, and far more 
numerous.  They were removed from this analysis so as not to misrepresent a loss of GR1+ cells 
as a relative increase in F4/80+ cells.  MaFIA ablation also resulted in an approximate 200% 
increase in total HSPC over ethanol vehicle injection (Figure 3-7b). However, these expanded 
HSPC came at a cost.  Nearly all the LKS cells were in fact CD48+ (Figure 3-7b,c); the MPP 
population had robustly expanded at the expense of the HSC.  500,000 of the expanded cells 
were competitively transplanted into lethally irradiated recipients as described above but despite 
3-fold relative LKS enrichment, MaFIA expanded transplants failed to compete as well as control 
BM (n= 5 animals) (Figure 3-7d). 
 To ensure that no apoptosis had been induced in the HSC directly by the MaFIA system, 
we grew stromal cultures from MaFIA depleted bone marrow and added wildtype dsRed-HSPC.  
HSPC co-cultured with MaFIA depleted stroma grew robustly (Figure 3-8a). Upon flow cytometric 
analysis however, the phenotypic make-up of the expanded cells was biased toward more 
mature, lineage dedicates blood cells, and the LKS, CD48- compartment had nearly vanished 
(Figure 3-8b). Pan-macrophage ablation, though it expands MPP, does so at the expense of HSC 





Something unique about 999-mediated macrophage depletion allows for the expansion 
of MPP cells while preserving the HSC.  Removing all macrophages, though it may cause a flurry 
of hematopoietic activity, appears detrimental to long-term HSC stemness.  This once again 
exemplifies the importance of the physiologic co-culture as a platform to maintain HSC function.  
Attempts to isolate pro-support signal producing cells from the complex microenvironment have 
proven to be extremely challenging; likely because the very metric used to measure that support 
(expansion) contradicts the HSC preferred functional state (quiescence).  Increasing functional 



























Vav-DTR and FACS purification fully eliminated macrophages from stromal culture; in 
contrast, 999 treatment and MaFIA mediated ablation resulted in partial depletion.  HSPC 
support seems directly proportional to macrophage content yet somehow full and partial 
macrophage depletion conferred similar HSPC support augmentation.  Furthermore, 999 and 
MaFIA depleted microenvironments support very different types of HSC growth ex vivo.  We 
wondered if these ablation methods might be specifically targeting unique subsets of 
macrophages in the stroma.  We spoke in the introduction of M1/M2 polarization of 
macrophages, and the scope of signaling programs that macrophages are capable of performing.  
To this end, we analyzed mature stromal cultures before and after depletion by flow cytometry 
for informative polarization markers. 
Discrepancies in macrophage polarization following 999 stromal treatment suggest 
polarization ratios play a role in 999 mediated HSPC proliferation signaling.  We have identified 
that signal as TGFβ and how that presence or absence of TGFβ signaling alone in the bone marrow 
is sufficient to elicit quiescence or proliferation, respectively. 
 
Results 
 Following our typical 16 day maturation period, untreated stromal cultures consisted of 
both CD45+ and CD45- populations. Of the CD45+ population, cells were notably: CD11b+, 
CD16/32+, F4/80+, CD169-, Gr1-Low.  In addition, these cells had a range of expression of CD115 
(CSF-1 receptor), CD206, CD14, CD16.2 and CD11c (Figure 4-1a).  Stromal macrophages do not fit 
perfectly into a well characterized subpopulation based on these expression patterns, however 
 62
several of the polarization markers are characteristic of “M2-like” tissue resident macrophages.  
We were particularly intrigued by the bi-modal distribution of class 2 major histocompatibility 
complex (MHCII) on these cells. 
We isolated MHCII-High and Low macrophages by FACS, allowed them to recover for four 
days and stained for the previously variable surface antigens to determine if any of those variable 
antigens were preferentially expressed on MHCII-high or low cells. Although MCHII-high and low 
cells expressed similar levels of CSF1R (CD115), CD14, and CD16.2, Class II high cells appear to 
preferentially express higher levels of the M2 marker CD206, and lower levels of the dendritic 
cell marker CD11c (Figure 4-1b). 
MHCII is a key protein involved in antigen presentation by macrophages, dendritic cells 
(DC), and other phagocytes.  Note that stromal CD45+ cells do not highly express CD11c, a 
common DC marker.   999, being a thiophene, contains sulfur and is therefore bright yellow in 
color, it even auto-fluoresces given the right conditions.  By exciting at high energy wavelength 
(405nm) and using a GFP emission filter we are able to observe an auto fluorescent signature 
somewhere near 500nm.  As such we were able to directly visualize 999 phagocytosis by MHCII 
high stromal macrophages, (Figure 4-2); in contrast, MHCII low stromal macrophages do not 
appear to engulf 999.  The compound also appears to be unable to enter CD45- cells.  We 
therefore propose that 999 may not actually be synthetically lethal to this subset of macrophages 
but rather selectively administered.  MHCII high macrophages were also observed in what appear 
to be various states of apoptosis following massive phagocytosis of 999.  Whereas MaFIA ablation 
appears to kill stromal macrophages regardless of MHCII status (Figure 4-3a), 999 preferentially 
removes MHCII high macrophages from the stroma (Figure 4-3b, c).  We propose that it is this 
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MHCII high selectivity of 999 that allows treated cultures to uniquely expand MPP in culture while 
maintaining HSC function.  This is consistent with our observation that these two populations of 
macrophages express similar levels of CSF1-R, the receptor driving MaFIA regulated macrophage 
depletion.  
Although MHCII is typically expressed on the more phagocytic “M1-like” macrophage, 
most of the surface markers on stroma macrophages were predominantly “M2-like”.  Due to the 
recent surge in manuscripts identifying TGFβ as an important paracrine signaling paradigm 
regulating HSC quiescence (Introduction) as well as its dimorphic expression between M1 and 
M2 polarized macrophages, we hypothesized that TGFβ may be disproportionately expressed 
between these two cell populations. Indeed, TGFβ mRNA is expressed nearly ten-fold higher in 
MHCII-hi macrophages than MHCII-lo or CD45- stromal cells (Figure 4-4a) . 
 To confirm these results, we assessed the total TGFβ present in 999 treated and untreated 
stromal cultures by enzyme linked immunosorbent assay (ELISA).  ELISA works by binding target 
antigen (in this case TGFβ) to a capture antibody coated surface.  Signal antibodies are then 
added, activated and detected.  Capturing the antigen on the surface is necessary to detect 
unbound target protein from being lost in the various wash steps.  We anticipated a reduction in 
free total TGFβ following 999 treatment but saw no change (Figure 4-4b).  While ELISA was 
conducted in cultured media free of FBS (known to contain exogenous TGFβ), under normal 
culture conditions, our growth media contains high quantities of FBS.  We therefore hypothesized 
that 999 may lead to a decrease in TGFβ activation rather than total secretion.  ELISA for active 
TGFβ did reveal a slight decrease following 999 treatment, however these results were highly 
variable (Figure 4-4c). 
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 It was surprising that 999 treatment did not result in a reliable decrease in total TGFβ 
production, given that that the MHCII-high cells were being selectively killed.  We looked deeper 
and deconvoluted TGFβ mRNA expression following 999 treatment.  We found that while total 
TGFβ may be unchanged, there is a significant decrease in TGFB-1 expression and a 
compensatory increase in TGFβ3 expression (Figure 4-4d). 
 To determine the effects of TGFβ1 signaling on HSPC growth potential in the ex vivo co-
culture setting, we added exogenous recombinant TGFβ1 to stroma/HSPC co-cultures and once 
again measured the total hematopoietic outgrowth.  Adding TGFβ1 in this manner dramatically 
reduced HSPC outgrowth to approximately 25% of normal co-culture (Figure 4-5a). Pretreatment 
of stroma for three days prior to HSPC and TGFβ1 addition was unable to restore augmented 
support capacity in the presence of recombinant TGFβ1. 
In addition, we also inhibited TGFβ1 signaling to co-cultured HSPC directly by adding the 
selective TGFβ1 inhibitor SB431542.  The resulting outgrowth was increased to levels nearly 
comparable to 999 augmentation (Figure 4-5b). Interestingly, 999 treated stroma appeared to 
increase support capacity even further by additional TGFβ1 inhibition. 
Chronic knockout of TGFβ receptor has been reported to significantly alter intercellular 
regulation among numerous hematopoietic cell types (Oshima, Oshima, & Taketo, 1996). We 
crossed a tamoxifen-inducible constitutive CRE with a lox-p floxed TGFβ receptor type 2 to drive 
acute global ablation of the TGFβ receptor aver tamoxifen injection.  Tamoxifen was 
administered over five days by three IP injections as well as added to feed, we confirmed loss of 
TGFβ receptor by qPCR (Figure4-6a). 
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Following receptor knockout (RKO), bone marrow composition was assessed by 
quantitative flow cytometry.  While the total number of HSC in the bone marrow of this this 
mouse appear unaltered (25000 in KO vs 25000 in control), the number of total MPP (LKS 48+) 
increased 10-fold (Figure 4-6b, c).  To confirm that this was specifically due to the ablation of 
TGFβ signal, we co-cultured these RKO HSPC with wild-type stroma.  We found that HSPC lacking 
the type 2 unit of the TGFβ receptor exhibit much more growth in vitro than HSPC with the 
receptor intact – even more-so than normal cells grown on 999 treated stroma (Figure 4-7a). 
However, co-culturing these cells on 999 treated stroma did not further increase this growth.  
This further suggests that HSPC growth augmentation with 999 stromal treatment reflects a 
reduction in TGFβ quiescence signaling from stromal macrophages to the HSPC. 
To confirm that MPP expansion following acute TGFβ inhibition preserves HSC function, 
unlike similar expansion seen in MaFIA macrophage ablation, bone marrow was similarly 
competitively transplanted.   Four week data suggests that these HSPC have increased 




These transplantations resemble those of 999 expanded co-cultures (Figure 1-7), implying 
once again that while greater numbers of HSC have previously been shown to increase successful 
engraftment probability (Introduction), expanding the MPP compartment prior to 
transplantation while maintaining HSC also assists overall success of transplantation. 
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999 being uniquely phagocytosed by MHCII-HI (likely antigen presenting) macrophages 
causes their selective depletion.  Dynamic polarization of macrophages suggests that these cells 
cannot be selectively and permanently removed from culture, however an ongoing culture 
treatment is possible with a compound such as 999.  These cultures can maintain HSPC in a 





























Animals were housed and bred in accordance with IACUC guidelines.  The following mice 
strains were obtained from Jackson Laboratories: C57B6/J – 0664, SJL – 2014, actin-dsRed – 6051, 
actin-GFP – 0329, VavCre – 8610, LyzMCre – 4781, iDTR – 7900, MAFIA – 5070, Cd11bDTR – 6000, 
TGFβR2 – 12603, CreER – 8463, mTmG – 7676.   
For in vivo tamoxifen induced recombination (TGFβR knockout) Tamoxifen (Sigma T5648) 
was resuspended at 10mg/mL in or Corn oil (Sigma C8267). Adult mice received three 
intraperitoneal (IP) injections over five days of 100uL of the above (approximately 3X 50mg/kg) 
and given 24hr rest before sacrifice.  In addition, mouse food was replaced with Tamoxifen Chow 
(Harlan Laboratories TD.1308603) during the final three days of induction (additional 
40mg/kg/day). 
MaFIA mice were ablated by administration of (10mg/kg) B/B homodimerizer (Clontech 
632622). Injection was diluted in sterile saline immediately before injection to 1mg/mL and mice 
were given three IP injections every other day over five days, average injection volume of 200uL.  
18.5% Ethanol (Sigma E7023) in sterile saline was injected similarly as vehicle only control.   
For in vivo DTR ablations, 10mg/kg Diphtheria Toxin (List Biological Labs) was injected IP 
three times every other day over five days.  Injection was resuspended to 2ug/mL in sterile saline, 
average injection volume was 200uL.   
Host mice for transplantation were administered full lethal dose of ionizing irradiation 
(10.5 gy) from J.L. Shepherd & Associates Cesium-137 based gamma-ray irradiator, with an 
approximate dose rate of 1.28 Gy (128 Rad)/min. Irradiation exposure was split into two doses 
90min apart with addition 90min recovery time before transplantation. 
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Cell Culture: 
Primary stromal cultures were generated from 12 week-old mice.  Long bones (femur, 
tibia, hips) from one mouse were extracted, cleaned, and crushed in a mortar and pestle in PBS 
supplemented with 0.5% FBS (SERADIM 1600-500).   Elute was filtered through a 70µm cell 
strainer and bone chips were rinsed to extract any additional cells that may have remained stuck 
to the bone. Extracted cells were plated in 150cm2 tissue culture flasks in 30mL Alpha Minimum 
Essential Media (AMEM) (Corning 10-010-CV) supplemented with 20% FBS and 1% 
penicillin/streptomycin; no cytokines were added.  Cultures were grown at 33°C 5% CO2 and 
passaged three times over 16 days (days 10, 13, 16). 
After 13 days, CD105 enrichment was performed (screen only) by biotinylating CD105+ 
stromal cells in liquid suspension (Biolegend 120404) and incubating labeled cells with 
streptavidin (SA) conjugated M-280 magnetic beads (Life Technologies 60210).  Cells were 
manually separated with a magnet.   At the end of 16 day culture, optical bottom 384-well tissue 
culture plates (Corning 3712) were coated in 10ug/mL fibronectin (Millipore FC010) for 60min at 
room temperature to promote stromal binding and stroma was plated at 2200 cells per well to 
achieve a fully confluent monolayer.  MaFIA depleted stroma was maintained in 100nM B/B 
homodimerizer.  Vav-DTR ablated stromas were ablated in vitro by addition of 33.3ug/mL DT for 
72 hours.  Experiments not requiring microscopy readout were plated in lower density (96, 12, 
or 6-well) format. 
HSPC were isolated by FACS.  Long bones were harvested from no less than twenty 8-12 
week-old mice per iteration of the screen (screen only).  Cleaned bones were lightly cracked in 
PBS with 0.5% FBS with mortar and pestle to expose bone marrow, and filtered through 70µM 
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cell strainer.  Bone marrow elute was centrifuged at 500G for five minutes in a refrigerated 
centrifuge and resuspended in 0.5mL hypotonic ACK red blood cell (RBC) lysis buffer per mouse. 
RBC were lysed on ice for five min and buffer was quenched by addition of nine volumes of PBS.   
Cells were again filtered through 40µm cell strainer to remove lysed RBC membranes. Cells were 
stained and sorted as described below.  HSPC were added to stromal cultures in assay plate at 
300 cells/well on stromal monolayer to a total volume of 50µL 72 hour stromal conditioned 
media.  HPSC co- and tri-cultures were grown five days at 33°C in AMEM+20% FBS unless 
otherwise indicated.  Where applicable, primary macrophages were isolated by FACS as 
described below and added to HSPC/Stromal co-culture.     
For small molecule screening, immediate HSPC support was provided by addition of 
additional cytokines: [10ng/mL IL3 (Peprotech 213-13), 10ng/mL FLT3 (Peprotech 250-31L), 
10ng/mL TPO (Peprotch 315-14)].  Compounds were received arrayed from the Broad Institute 
at 10mM in DMSO and added to co-cultures at working concentrations of 20µM in 0.2% DMSO 
eight hours after plating.  Small molecules for subsequent studies were added to cell lines or co-
cultures at 10µM in 0.1% DMSO (Sigma D14350) unless otherwise indicated.  Recombinant 
human TGFβ1 (Biolegend 580706) being cross reactive with mouse, was added to co-cultures at 
5nM.  TGFβ1 inhibitor SB431542 (Tocris 1614) was added as indicated.  
Long term HSPC co-culture was performed with serial stromal support.  HSPC were 
isolated and grown in co-culture as described for seven days after which they were removed and 
re-plated onto fresh P3 stromal culture for additional seven days per passage as required.   
High Throughput Fluorescence Microscopy 
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Total hematopoietic outgrowth was determined by 4x full-well-capture high throughput 
flourescence microscopy (IXMicro; Molecular Devices – Screen) (InCell2000; GE – remaining 
studies).  Four tiled images were taken per well, in both GFP and dsRed channels to capture the 
entire surface of the well (IXmicro only, InCell2000 captured entire well in single image) at 50ms 
and 600ms exposures, respectively.  These images were automatically stitched together, and 
analyzed with ImageJ. Intensity thresholds were set manually per plate to distinguish cells from 
background fluorescence and pixel intensity was converted to binary for high throughput 
automated analysis. 
Confocal Microscopy: 
CD45+, MHCII-High and CD45+, MHCII-Low cells were sorted by FACS and plated on 
chamber slides and treated with 10µM 999 for 72 hours.  Chambers were removed and cells were 
rinsed with PBS and briefly fixed and permeabilized 10min at room temperature with 
Cytofix/Cytoperm solution (BD 554722).  Slides were rinsed again, and stained with 10µg/mL 
propidium iodide (ThermoFisher P3566) for five min at room temperature before mounting 
coverslips.  Slides were imaged with 100X oil lens on Nikon A1 Confocal.  Brightfield, TRITC (PI), 
GFP (999 background) and custom (999) fields were captured.  999 was captured using 405nm 
excitation and GFP emission filter.  GFP emission was also captured with 488nm excitation to 
confirm there was no background auto fluorescence (not shown).  Images were analyzed with 
Fiji. 
Competitive Transplants: 
Competitive murine transplants were performed in lethally irradiated cogenic mice.  Total 
hematopoietic outgrowth of 2000 input HSPC were co-injected with 106 nucleated bone marrow 
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cells as competitors where indicated or 5X105 nucleated bone marrow cells were co-injected with 
5X105 competitors where indicated.  IV injections were performed by tail vein, cells and 
competitors were pooled in sterile saline in 200µL per injection.   
Single cell transplants from long term culture:  
After 14 days of culture 1/2000 the total 14 day growth of 2000 input HSPC (~5000 total 
cells) corresponding to the total outgrowth of one input HSPC was transplanted as described and 
competed against 500,000 competitor bone marrow cells (n=20 mice).   Similarly 1/2000 of the 
total outgrowth of 2000 HSPC grown in co-culture treated with vehicle alone (~0 cells) was 
transplanted (n=2 mice), and 25000 freshly isolated bone marrow cells statistically expected to 
contain one HSPC (n=10mice).   
Flow Cytometry: 
All antibodies used for flow cytometry were obtained for Biolegend and used at 2.5µg/mL. 
Cells were sorted with FACSARIAII (BD) and analyzed with either LSRII (BD) or Fortessa (BD).  HSPC 
were defined as Lin-lo, cKit+, Sca1+, CD48-.  HSPC were sorted from bulk bone marrow at 
approximately 40,000 cells/mouse with FACSAriaII at 70PSI and 70µM nozzle diameter.  Bone 
marrow macrophages for tri-cultures were CD45, F4/80, CD11b triple positive.  Fractionated total 
cell counts were obtained by quantitative flow cytometry. Bone marrow or well contents were 
collected and stained as appropriate. 2000 CountBright beads (Molecular Probes C36950) were 
added per sample and events were collected until 1000 (cultured cells) or 250 (femur) beads 





ELISA (Biolegend 436708) was conducted as instructed in 72hr FBS starved media, latent 
TGFβ was activated where applicable by 10 min acidification (supplied).  For mRNA extraction, 
cells were sorted directly into Trizol-LS (Thermofisher 10296028), nd purified with chloroform 
and RNeasy columns (Qiagen 74106).  cDNA was reverse transcribed (Applied Biosystems 
4387406) and quantified using TaqMan assays and Mastermix (Applied Biosystems 4440039) on 
BioQuant-3 RT-qPCR machine (Thermofisher). Taqman Assays Used: TGFβ1: Mm01178820_m1, 
TGFβ2: Mm00436955_m1, TGFβ3: Mm00436960_m1, iNos: Mm00440502_m1, Arg1: 
Mm00475988_m1, CSF1R: Mm01266652_m1, TGFβR2: Mm03024091, Gapdh: 






















 The HSC has been one of the most studied, yet most controversial cells of the last several 
decades.  Ease of isolation has led to incredibly precise characterization by flow cytometry and 
many creative techniques have evolved to access functional ability of the cell.  The HSC is surely 
setting the standard for stem cell research in general going forward.   
 One of the shortcoming of this field is the inability to easily grow these cells ex vivo.  
Researchers have been attempting to do so for half a century yet still rely on hundreds and 
thousands of donors to supply primary material for experiments.  We have devised technology 
to expand or maintain dissociated cells like HSC: growth media, incubators, etc as well as 
surrogate environmental cues and tissue specific nutrients (chemokines and cytokines).  Yet with 
all our modern tools, HSC and most other stem cells as well still require something more. They 
require a niche – the place the cell calls home. 
 It is no secret that proliferation of the HSC is tightly regulated, and we have long been 
searching to understand these regulatory systems in hopes that they will uncover the reasons 
that growing these cells has been so challenging.  One of the reasons these signals have been 
challenging to dissect is the complexity of the bone marrow in general.  According to pubmed, 
over 260 articles were published last year (2015) containing the search term “hematopoietic 
niche” – nearly one every day! Adding one’s favorite blood or bone cell to the search will almost 
certainly return specific results making at least two of the following claims: the cell maintains the 
HSC, the cell inhibits the HSC, or the cell maintain HSC stemness.  What is so elusive about this 
niche?  
Our organotypic co-culture screening system in unique in its ability to maintain cultured 
HSPC in the full physiological micro-environment of the bone marrow. As no single cell has yet 
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been able to provide total support necessary to maintain HSPC function over several days in ex 
vivo culture, we elected instead to preserve the niche as a whole. This screen found the small 
molecule “999” capable of expanding the overall hematopoietic capacity of this niche.     
Importantly, 999 treatment of bone marrow stroma selectively removes a sub-signal from this 
complex signaling environment while preserving the rest of the unknown obligatory support.  
Eventually these essential signals will be elucidated, but that is beyond the scope of this 
dissertation.    
 We discovered that a population of MHC class 2-high tissue resident macrophages in the 
bone marrow provide this signal to the HSPC.  Our data suggest that when enough of these cells 
are present in the bone marrow the TGFβ1 produced signals to the HSPC that quorum has been 
met as no further proliferation is necessary.  Selectively blocking this signal alone appears to have 
no effect of the HSC itself either in total prevalence or function but rather is a regulator of MPP 
proliferation and its subsequent progeny, consistent with physiological behavior of 
hematopoiesis. 
 999 selectively kills this subset of macrophages from organotypic culture.  While several 
methods exist for ablating macrophages, 999 is the first shown to selectively kill M2-like 
macrophages.  We have shown that this specificity is due to selective phagocytosis and that other 
stromal cells are unaffected.  This broadens the application of 999 beyond ex vivo hematopoiesis 
enhancement as a tool to manipulate macrophage polarization ratios in tissue.  Just as HSC has 
led the way for stem cell research, so too will this knowledge of the bone marrow niche and its 
signaling environment lead to better understanding of other stem cell niches. 
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 While this work has uncovered underlying niche biology, it also holds therapeutic 
promise.   Although this is ex vivo culture, we propose that controlled organotypic hematopoietic 
expansion still has deep impacts for HSCT therapy.  We showed that 999 mediated ex vivo 
expansion of HSPC maintains or improves engraftment ability over long term culture.  This 
satisfies a critical requirement currently absent in the future of medicine.  Long-term ex vivo 
culture opens the door to procedures on the HSPC that would be otherwise impossible in vivo.  
Precision medicine is largely restricted to cells that can be grown in vitro and modern genomic 
editing techniques require extensive ex vivo culture and selection.   
 Blood has been studied for thousands of years – indeed one of the first tissues (humors 
at the time) man sought to understand.  Today we are taught in basic biology about the various 
blood cells and their functions.  Between then and now, what we have learned about blood has 
changed the way we think about medicine and has saved countless lives.  As we approach a new 
era of cellular therapeutics, new understandings of current mysteries will undoubtedly change 
the future of medicine just as dramatically. 
 Today, nearly everyone will have some interaction with Cancer in their lifetime, either 
themselves or someone close to them.  It is the second leading cause of death in the US, and has 
already become far and away the focus of the medical research community.  Cancer represents 
- at its core, a shortcoming of the immune system.  Whereas other pathogens are detected and 
eliminated by this system, cancer, being is a disease of the self, remains cloaked.  Reprograming 
our immune system to recognize malignant self is rapidly gaining traction as a powerful 
therapeutic option.  Again however, these techniques require maintaining cells in an ex vivo 
environment.   
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 On the other side of the coin, but with equally devastating prognosis, is over-activity of 
the immune system.  Transplantation technology has advanced dramatically in recent decades 
and surgeons are able to transplant fully functional organ systems that integrate with a patient’s 
body nearly seamlessly.  Yet no matter how well connected, foreign tissue may still elicit a 
response from the bodies innate immune system.  This has become a major hurdle for organ 
transplantations as a patient must sometimes wait long periods of time for an appropriately 
matched donor while their condition deteriorates.  Additional complications, like GVHD even 
from presumably matched donor and recipient exacerbate this problem. 
 Synthetic tissue, made from cultured cells rather than donated en masse can sidestep this 
requirement.  Here again, stem cell therapeutics are poised to drastically change the way we 
perform medicine.  Just as understanding the function of cells revolutionized medicine in the last 
millennium; so too will understanding the regulation of cells in the future. 
 Stem cell niche biology has made great strides in the last decade as scientists have 
dissected complicated microenvironments into distinct cell-cell interactions.  Much of the 
mystery of organ systems and therefore the necessity to culture gross highly variable tissue, a 
practice commonplace in research of the 20th century (particularly in human biology), may soon 
become outdated.  As we go forward into the next decade these understandings will continue to 
evolve and lead to controlled reconstruction of complex biological microenvironments to answer 
evasive scientific questions.  Until we fully understand these systems however, it remains 
necessary to capture those unknown signals to prevent unintended modification of the 
microenvironment.  After all, if you want to know what happens in the bone marrow, the best 
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 Specific cell surface markers have since been identified and have become generally 
accepted as sufficient characterization to classify a cell as a HSC phenotypically, however 
demonstration of stem cell function remains a necessary standard to be met to call a given cell 
HSC. An HSC must certainly be hematopoietic (CD45+) but not express any surface marker 
associated with mature, lineage dedicated cells. These antigens (CD3, CD4, CD8a, CD11b, B220, 
Gr1, Ter119) are collectively referred to as “lineage”.  Furthermore, HSC and its closely related 
multi-potent progenitor (MPP) will both present cKit (stem cell factor receptor) and Sca1 
antigens; collectively these cells are hematopoietic stem and progenitor cells (HSPC) or LKS 
(Lineage-, cKit+, Sca1+).  MPP as their name implies, share the HSC's multipotent capability but 
notably lack self-renewal capacity and are therefore not stem cells.  HSC are classically 
distinguished from MPP by the presence of CD150 (SLAM) and absence of CD48 although several 
other markers continue to be identified to further classify subpopulations (Kiel et al., 2005; 
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In this review we describe the phenomenon alluded to in the introduction that a 
malignant microenvironment may proceed and encourage tumor formation.  In addition to 
resident fibroblasts, endothelial and epidermal cells, bone marrow derived mesenchyme is 
recruited to the tumor site and gives rise to cancer associated fibroblasts (CAFs).   
Non-fluorescent colon carcinoma (MC38) cells were injected into previously described 
actin-dsRed mice. The resulting subcutaneous tumor contained many of these recruited (red) 
cells, which express CD105 and CD140a markers characteristic of BM stroma cells. 
This concept of a malignant microenvironment is further supported by our previous work 
in Nature. Impaired function in niche forming cells, here by deleting Dicer1 in osterix+ 
osteoprogenitior cells, created a malignant bone marrow niche and mice developed 
myelodysplasia.  Even transplanting healthy blood cells into such an environment caused disease 
(Raaijmakers et al., 2010). 
Our review suggests that as new markers for mesenchymal antigens and gene expression 
are developed and identification of sub-populations is improved, our understanding of both the 
healthy and malignant signals they transmit will improve with them.  Microenvironmental 
(specifically mesenchymal) therapies are under development and will likely become an 
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The HSPC/stromal co-culture system can easily be adapted to grow nearly any 
hematopoietic cells normally residing the the bone marrow.  This has been particularly useful in 
studying malignancies.  In much the same manner as this HSPC screen, we also screened an 
arrayed library of small molecules on a popular acute myeloid leukemia (AML) model MLL-AF9 
(Hartwell et al., 2013). In addition, we adapted the platform to incorporate selective shRNAi 
knockdown within the hematopoietic cell.  
In this study, conditional knockout of the transcription factor ZFX in leukemia initiating 
MLL-AF9 cells (LIC) resulted in significantly delayed AML development in vivo (also T-ALL).  ZFX 
deletion also decreased expression of iDH2, PTPM1, among others.  Here we used shRNAi in 
stromal co-culture to confirm lethality in AML to knockdown of these downstream targets of ZFX.  
We found that knockdown of these targets impaired AML progression in ZFX-wt leukemia 
initiating cells.  Furthermore, over expression of iDH2 or PTPM1 in ZFX-deficient AML was able to 
partially rescue ZFX dependent propagation. 
We proposed in this study that ZFX, while not required for normal self-renewal of the 
HSC, becomes essential when that cell transforms into an LIC and becomes “locked” in an 
undifferentiated state.  Under these conditions, ZFX, in conjunction with Myc, binds to active 



































Hematopoietic stem cell dysfunction underlies the progressive 
lymphocytopenia in XLF/Cernunnos deficiency. 
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XLF is an important component of the non-homologous end joining (NHEJ) pathway for 
repairing double strand breaks in DNA.  Patients with mutations in XLF exhibit progressive and 
severe lymphocytopenia despite normal V(D)J recombination, a process that relies heavily on 
NHEJ of double strand DNA breaks.  We characterized the XLF -/- mouse model by flow cytometry 
and found that as these mice age they mimic the human phenotype.  Relative proportion of B- 
and T-cells in the bone marrow and spleen collapse. We further show that HSC function is 
impaired as XLF-deficient HSC (particularly those from aged donors) fail to reconstitute the bone 
marrow. 
Recall the importance of 999 expanded HSPC ability to reconstitute at stable and 
endogenous lineage ratios.  We propose in the main text that ex vivo over-expansion of the HSC 
causes genomic instability.  We show here that genomic instability, here caused by XLF knockout 
(despite multiple redundant repair pathways) experience increased failure to perform double 
strand breaks with high fidelity. This not only skews the functional ability of the HSC to repopulate 
the hematopoietic system properly but also significantly hinders engraftment potential 
measured by competitive bone marrow transplantation (see materials and methods).  XLF KO 
HSC, particularly those from aged donors who experience a lifetime of this increased genomic 




















Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular 
stromal potential. 
 
Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, Levin D, Schwartz MG, Uygur A, 
Hayakawa Y, Gross S, Renz BW, Setlik W, Martinez AN, Chen X, Nizami S, Lee HG, Kang HP, 
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A, Carpenter J, Glaire M, Nair A, Renders S, Manieri N, Muthupalani S, Fox JG, Reichert M, 
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Here we identify a novel cell within the bone marrow capable of generating bone, 
cartilage and reticulocytes.  Gremlin-1 expressing cells are rare, self-renew, are multipotent, and 
are present during periods of significant bone growth and remodeling.  We propose that these 
cells are mesenchymal stem cells (MSC) consistent with those findings.  Prior models have 
proposed a Nestin+ cell as an early MSC, however we demonstrate that those cells fail to reliably 
form colonies in vitro as would be expected of an MSC and are significantly morphologically 
distinct from the cells they are reported to produce. 
Gremlin+ cells not only readily give rise to multiple lineages when isolated by FACS and 
grown in vitro but do so in vivo under the physiological control of the microenvironment.  We 
observed both fully mature bone forming osteoblasts and cartilage forming chondrocytes in the 
bone marrow originating from P1 lineage traced Gremlin+ cells.  We also showed that Gremlin 
cells are recruited to the repair site when challenged by femoral fracture and their direct progeny 
is integrated into the repaired tissue. 
Notably, Gremlin+ MSC, like HSC, spend much of their life in a quiescent state.  After a 
developmental surge, relative frequency of these cells becomes minimal and the majority of 
tissue maintenance is carried out by more mature progenitors.  While at first glance this may 
seem redundant, it is these emergency stem cell reserves that allow us to recover from massive 



































IL-17 producing mast cells promote the expansion of myeloid-derived 
suppressor cells in a mouse allergy model of colorectal cancer. 
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 Bone marrow and tumor microenvironmental signals have tremendous control over the 
production and recruitment of the cells that will come to inhabit them.  Myeloid derived 
suppressor cells (MDSC) shown here to suppress T-cells and promote tumor growth, are 
stimulated by IL-17. Normally histamine prevents overgrowth of both the MDSC population and 
IL-17 secreting mast cells through a cis-feedback mechanism (Appendix G) but in the absence of 
histamine, (genetic KO), these MDSC and IL17 producing mast cells are permitted to accumulate. 
 IL17 is a pro-inflammatory cytokine, when the immune system is challenged, here by an 
allergic response anti-inflammatory IL4 and IL17 are both upregulated so as to preserve 
polarization ratios in the microenvironment.  In the histamine knockout setting, this balance is 
shifted toward a more inflammatory microenvironment, suppressing T-cells and promoting 
tumor growth.  
 We have shown that polarization state of the myeloid/macrophage compartment is 
essential in regulating growth of the HSPC and suggested that the ability of 999 to favorably alter 
the composition of this compartment may have implications for oncology.  This study is in 
accordance with that hypothesis, unfavorably altering myeloid polarization by histamine deletion 


































A histamine-dependent circuit regulates myeloid-biased hematopoietic 
stem cells 
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Here we identify a novel myeloid biased (MB) sub-class of HSC marked by histadine 
decarboxylase (HDC).  These cells respond directly and specifically to myeloid challenge (LPS) and 
are thus recruited into cell cycle.  We further show that these MB-HSC are regulated by a 
paracrine feedback loop from their lineal descendants and that histamine itself is that factor.  We 
demonstrate that the product of this enzyme, histamine, produced by the descendants provides 
a quiescence signal to the MB-HSC. This signal limits excessive proliferation and preserves stem 
cell function, while removal of histaminergic tone leads to robust expansion and ultimately HSC 
exhaustion.  We also propose that this cis-feedback system is a type of quorum sensing tool for 
the myeloid compartment within the bone marrow and may assist in reestablishing homoeostasis 
following myeloid demand. 
Culturing HSC ex vivo in the co-culture system allows us to manipulate the signals that 
HSC receive from their microenvironment.  Just as we were able to synthetically create or inhibit 
TGFβ signaling to HSPC by adding either the protein or inhibitors, here too we directly alter the 
histamine signal HDC+ HSC are exposed to by addition of agonist or antagonist to HSC/stromal 
co-culture. 
This work also underscores again the importance of maintaining quiescence in self-
renewing cells.  We demonstrate that not only does loss of histamine mediated quiescence lead 
to premature HSC exhaustion, but the same quiescence signal protects MB-HSC during injurious 
stress like LPS or irradiation. 
The summary only is included for this unpublished study. 
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SUMMARY 
Myeloid-biased hematopoietic stem cells (MB-HSC) appear to be crucial in medicine in 
the context of transplantation, inflammation and recovery from radiation injury. However, 
nothing is known about their physiology in their native marrow niche. Here, we identify a 
novel paracrine physiologic circuit that plays a central role in all these processes, thereby 
tethering MB-HSC to their marrow niche.  We show that histidine decarboxylase (Hdc) 
marks quiescent MB-HSCs. Histamine, the paracrine factor produced by lineal 
descendants in close anatomical proximity to MB-HSCs, feeds back through the H2 
receptor (H2R) on these biased HSCs in a cis-acting manner to promote their 
quiescence/self-renewal following provocation. Removal of histaminergic tone enforces 
cell cycle entry, loss of serial transplant capacity (particularly in myeloid reconstitution) 
and sensitizes animals to chemotherapeutic injury. Notably, myeloid “demand”, induced 
by lipopolysaccharide (LPS), specifically recruits MB-HSCs, but not unbiased HSCs, into 
cycle. In the absence of histamine, the system fails to reset cycling stem cells back into 
quiescence, leading to stem cell exhaustion. Remarkably, injection of a H2 agonist in vivo 
enforces the quiescence of MB-HSCs and protects these cells from DNA-damage caused 
by ionizing radiation (IR) and exhaustion after sepsis. Intrinsically primed stem cells are 
recruited to meet the lineage-specific physiological demands of an organism, and 
restored to homeostasis by a paracrine factor – histamine - produced by their lineal 































 In addition to the manuscripts in the previous appendices, the organotypic co-culture 
previously described has proven to be exceptionally valuable as a drug screening platform and as 
a tool for building model systems to better understand the biological process of hematopoiesis.  
This platform has been adapted to incorporate various primary cells including multiple cancer 
models, as well as lineage specific hematopoiesis.  This flexibility of the platform has generated 
many collaboration opportunities (some still in preparation) and we have attempted to share this 
expertise with the scientific community at large.  This appendix simply contains a list of published 
abstracts from some of those opportunities. 
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